Back to Search Start Over

Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases

Authors :
Caterina Foti
Paolo Romita
Francesca Ambrogio
Carlo Manno
Raffaele Filotico
Nicoletta Cassano
Gino Antonio Vena
Aurora De Marco
Gerardo Cazzato
Biagina Gisella Mennuni
Source :
Life, Vol 12, Iss 12, p 2002 (2022)
Publication Year :
2022
Publisher :
MDPI AG, 2022.

Abstract

Background: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease that can affect patients’ quality of life. Dupilumab is the first biologic agent approved for the treatment of patients with inadequately controlled moderate-to-severe AD and its mechanism of action is based on the inhibition of the interleukin (IL)-4 and IL-13 signaling. There are only a few data on the safety of dupilumab in AD patients with comorbidities, including kidney disorders. Materials and Methods: Descriptive retrospective series of three patients with chronic kidney diseases (Alport syndrome, IgA nephropathy, and hypertensive nephrosclerosis, respectively) receiving dupilumab for their concomitant severe AD. Results: Treatment with a standard dosage of dupilumab caused a relevant improvement of AD in all patients without any adverse events or worsening of renal function. In a patient with severe renal failure, the drug was effective and well tolerated without the need for any dose adjustments, also after the initiation of peritoneal dialytic treatment. Conclusion: Our case series suggests the use of dupilumab as an effective and safe treatment for AD patients suffering from renal diseases, although additional studies are required to confirm such preliminary findings.

Details

Language :
English
ISSN :
20751729
Volume :
12
Issue :
12
Database :
Directory of Open Access Journals
Journal :
Life
Publication Type :
Academic Journal
Accession number :
edsdoj.8cb79f237884cce9f02247a3a495a33
Document Type :
article
Full Text :
https://doi.org/10.3390/life12122002